Haoxi Health raises about $4 million via direct offering
Jul 10, 2026, 1:17 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The direct sale of up to 10M new shares (or warrants) at a fixed price raises dilution risk, typically pressuring micro-cap equities. The absence of a strategic buyer or use-case to quickly monetize cash may not offset near-term dilution; however, the cash could improve runway if used prudently. Pre-funded warrants offer some near-term relief but still set up future dilution upon exercise.
AI summary
What happened, with direct paths to the underlying reporting
Haoxi Health Technology said it is conducting a registered direct offering to sell 10 million Class A shares (or pre-funded warrants) at $0.40 per share, targeting roughly $4 million in gross proceeds. The deal is expected to close around July 13, 2026, with Univest Securities as the sole placement agent. The financing dilutes current holders but provides cash to support operations and growth initiatives in China’s healthcare marketing arena.
Haoxi to raise about $4M with 10M shares at $0.40; close around July 13.
Offering is a registered direct offering under Form F-3; Univest Securities is agent.
Close date subject to customary conditions; cash may support operations.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
